Therapy Insight: preserving fertility in cyclophosphamide-treated patients with rheumatic disease
Mary Anne Dooley* and Raj Nair
Correspondence *Division of Rheumatology and Immunology, University of North Carolina, 3330 Thurston Building, CB#7280, Chapel Hill, NC 27599-7280, USA
Email mary_dooley@med.unc.edu
Cyclophosphamide is an important therapy for patients with severe rheumatic diseases; it is, however, responsible for gonadal toxicity. There are a number of interventions aimed at reducing this toxicity, including estrogen-containing oral contraceptives, hormone agonists and antagonists of gonadal receptors in females, and testosterone therapy and storage of gametes for male patients. These strategies are outlined in this article.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Bone loss goes beyond estrogenNature Medicine News and Views (01 Jun 2006)
Endocrinology: Has the prolactin inhibiting peptide at last been found?Nature News and Views (08 Aug 1985)
See all 7 matches for News And ViewsRESEARCH
Ovarian recovery after stem cell transplantationBone Marrow Transplantation Original Article
See all 7 matches for Research